Cybiont’s Long / Short Systematic Portfolio: September 2023 & Performance to Date (3 months)

Beginning in July 2023, we are publishing our returns from our $ neutral Long/Short Systematic Portfolio.1

We believe that the reporting of earnings is our best catalyst for performance. As banks report, it either validates our modeling of the industry’s risks and opportunities or it doesn’t. Accordingly, in the interim between earning seasons, we bring the fund’s gross exposure down to protect our performance from idiosyncratic catalysts; such as an acquisition of a short or an unfavorable regulatory event for a long. For September we brought our Gross Leverage down from an average of 214% of NAV in July to 154% in September and 154% in August.

Reflecting our overall view that near-term prospects for banks will disappoint analysts’ expectations for Net Interest Income (See Net Interest: Rising Beta, August 25, 2023), we moved to an average Net Short Exposure of 5% in August from July’s Net Long exposure of 1%. In September, we averaged Net Short exposure of 7%.

For October, we will be increasing Gross Leverage to 220% and maintaining Net Short Exposure of 5%.

September Performance

We lost 90 bps in September compared to a loss for the KBW Bank Index of 3.94% and a loss of 5.71% for the KBW Regional Bank Index (which better overlaps our investable universe). Our Sharpe Ratio was negative for month given our underperformance to the risk-free rate, which averaged 5.33% for the month. Our volatility, as targeted, remains lower than the various broader indexes as well as the fund’s level during earnings season. Annualized volatility was just 5.26% in September, compared to KBW Bank Index’s of 16.62%.

To Date Performance

We’re pleased with our out performance to-date (recognizing that a 3-month return isn’t much of a trend). Our strategy of avoiding downside risk paid off this month as the BKX moved to a loss to comparable date of 2.40% compared to our to-date gain of 5.64%.

We’re thrilled with our nearly 40% annual return to date (compared to the BKX’s almost 14% annualized loss for the three months); and we were able to accomplish this return with a little more than a third of the volatility of the BKX. As a result of our low volatility, we’ve generated a Sharpe Ratio of almost 4. Given our protection of the downside, we generated a Sortino Ratio of 114.

As a reminder, the governing risk parameters of the fund are as follows:

From time to time we also take more concentrated positions in high conviction ideas; but that is NOT part of this portfolio or strategy. Instead, we are operating by what we define as “Quantimental” wherein we engage in quantitative strategies derived relative to proprietary fundamental variables that create markers for the risks and opportunities that our macro analysis tells us are in play in any given banking regime.

Cybiont’s Quantimental Approach

Nothing here is intended as an offer to sell, or a solicitation of an offer to buy the interests described herein. Such offer or solicitation may only be made to qualified offerees by means of a confidential private offering memorandum or confidential explanatory memorandum (each a “Memorandum”) which contains important information (including investment objective, policies, risk factors, fees, tax implications and relevant qualifications), and only in those jurisdictions where permitted by law. Interests in Cybiont Capital, LLC shall not be offered or sold in any jurisdiction in which such offer, solicitation or sale would be unlawful until the requirements of the laws of such jurisdiction have been satisfied.

Before making an investment decision with respect to the Funds, potential investors are advised to carefully read the Memorandum, the partnership agreement of the Funds and the related subscription agreement, and to consult with their tax, legal and financial advisors.

An investment in the Funds is speculative and involves a high degree of risk. Opportunities for withdrawal and transferability of interests are restricted. There is no secondary market for the interests, and none is expected to develop. Leverage may be employed in the portfolio, which can make investment performance volatile. An investor should not make an investment unless it is prepared to lose its entire investment. The fees and expenses charged in connection with this investment may be higher than the fees and expenses of other investment alternatives and may offset profits.

  1. ↩︎

Authors

  • 30-year career as a Bank & FinTech sector stakeholder with substantive roles as investor, policy maker, regulator, operator, analyst, strategist, and advisor.

    View all posts
  • Entrepreneur, & Advisor with more than 30 years of proven innovative analytical skills delivering market-leading investment advice on Financial Institutions to many of the world’s leading global asset management firms. Success in Europe, Latin America, the U.S., and Canada, having held senior leadership roles on the buy-and sell- side as well as in financial institutions.

    View all posts


Leave a Reply

About Us

We are your banking experts.

Private Equity: We are a trusted partner for family offices and other investors seeking to invest in U.S. banks in the private markets. We source investment opportunities and provide diligence services and ongoing monitoring of bank investments for family offices and other investors for whom we provide cost-effective confidence for their financial company investments.

Public Markets: We structure bank investment portfolios providing risk-tailored strategies by systematically integrating fundamental and technical analysis building alpha-generating long/short portfolios from the nearly 300 liquid publicly traded banking companies in the U.S. markets. If you want bank equity exposure with tailored risk parameter’s, we’re your source.

Cybiont is…

Our Investment Philosophy

Recieve Cybiont’s analysis in your email as it’s released:

Discover more from Cybiont Capital, LLC

Subscribe now to keep reading and get access to the full archive.

Continue reading

Discover more from Cybiont Capital, LLC

Subscribe now to keep reading and get access to the full archive.

Continue reading